17 completed, 2 terminated, 1 approved for marketing, 1 unknown. 14 Phase 1, 9 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 14 | Completed 12, Unknown 1, Withdrawn 1 |
| Phase 2 | 9 | Completed 7, Terminated 2 |
| Phase 3 | 1 | Completed 1 |
Follow olaratumab: new trials by email Literature Review of olaratumab trials Research Report on olaratumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma Trabectedin, Doxorubicin, Olaratumab - Leiomyosarcoma | Phase 1 | Withdrawn | University of Miami | 2019-06-01 | 2019-03-18 | |
| OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma Patients Olaratumab, Dexrazoxane, Doxorubicin - Advanced Soft Tissue Sarcoma | Phase 2 | Terminated | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2 | 2018-11-12 | 2020-07-15 |
| Olaratumab Plus Trabectedin in Advanced Soft-tissue Sarcoma Patients Soft-tissue Sarcoma Patients Olaratumab and Trabectedin - Sarcoma, Soft Tissue | Phase 1 | Unknown | Grupo Espanol de Investigacion en Sarcomas | 28 | 2018-09-21 | 2023-03-27 |
| A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma Olaratumab, Doxorubicin, Ifosfamide - Soft Tissue Sarcoma | Phase 1 | Completed | Eli Lilly and Company | 24 | 2017-10-18 | 2020-09-10 |
| A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma Olaratumab, Pembrolizumab (KEYTRUDA®) - Soft Tissue Sarcoma | Phase 1 | Completed | Eli Lilly and Company | 41 | 2017-07-03 | 2024-10-23 |
| A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer Olaratumab, Nab-paclitaxel, Gemcitabine - Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | Completed | Eli Lilly and Company | 184 | 2017-06-22 | 2022-06-28 |
| Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma Multiple drug microinjection, CIVO device - Soft Tissue Sarcoma Adult | Phase 1 | Completed | Presage Biosciences | 23 | 2016-12-15 | 2021-09-24 |
| A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma Olaratumab, Doxorubicin, External Beam Radiotherapy - Soft Tissue Sarcoma | Phase 1 | Completed | Eli Lilly and Company | 51 | 2016-10-11 | 2019-08-12 |
| A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer Olaratumab, Doxorubicin, Vincristine - Neoplasm Metastasis | Phase 1 | Completed | Eli Lilly and Company | 68 | 2016-08-29 | 2020-05-20 |
| A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma Olaratumab, Gemcitabine, Docetaxel - Soft Tissue Sarcoma | Phase 1 / Phase 2 | Completed | Eli Lilly and Company | 310 | 2016-03-01 | 2022-05-09 |
| A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma Olaratumab, Doxorubicin, Placebo - Soft Tissue Sarcoma | Phase 3 | Completed | Eli Lilly and Company | 509 | 2015-09-14 | 2025-07-15 |
| A Study of Olaratumab in Japanese Participants With Advanced Cancer Olaratumab, Doxorubicin - Neoplasm | Phase 1 | Completed | Eli Lilly and Company | 25 | 2015-03-23 | 2021-02-17 |
| A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma Olaratumab, Doxorubicin - Sarcoma, Soft Tissue | Phase 1 | Completed | Eli Lilly and Company | 49 | 2015-01-22 | 2019-11-21 |
| A Study of Olaratumab (IMC-3G3) in Previously Treated Participants With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors Olaratumab - Gastrointestinal Stromal Tumor (GIST) | Phase 2 | Terminated | Eli Lilly and Company | 21 | 2011-08-01 | 2017-03-09 |
| A Study of Olaratumab (IMC-3G3) in Prostate Cancer Olaratumab, Mitoxantrone, Prednisone - Prostate Cancer | Phase 2 | Completed | Eli Lilly and Company | 123 | 2010-10-01 | 2019-09-20 |
| A Study of Olaratumab in Soft Tissue Sarcoma Olaratumab, doxorubicin - Sarcoma, Soft Tissue | Phase 1 / Phase 2 | Completed | Eli Lilly and Company | 148 | 2010-10-01 | 2017-04-14 |
| Study of the Safety and Pharmacokinetics of Olaratumab (IMC-3G3) in Japanese Participants With Solid Tumors Olaratumab - Malignancy, Metastasis | Phase 1 | Completed | Eli Lilly and Company | 16 | 2010-09-01 | 2017-04-14 |
| Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme olaratumab, ramucirumab - Adult Glioblastoma Multiforme | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 80 | 2010-07-01 | 2017-12-27 |
| A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Olaratumab, Paclitaxel, Carboplatin - Non-Small Cell Lung Cancer | Phase 2 | Completed | Eli Lilly and Company | 137 | 2010-01-01 | 2019-01-10 |
| A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer Olaratumab, liposomal doxorubicin - Ovarian Neoplasms | Phase 2 | Completed | Eli Lilly and Company | 125 | 2009-06-01 | 2019-09-26 |
Showing 20 of 22. Sign in to see all of them.
Sarcoma (11) · Neoplasms (4) · Leiomyosarcoma (2) · Neoplasm Metastasis (2) · Brain Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Gastrointestinal Stromal Tumors (1) · Glioblastoma (1) · Gliosarcoma (1) · Histiocytoma, Malignant Fibrous (1) · Liposarcoma (1) · Lung Neoplasms (1) · Lymphoma (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1)
Eli Lilly and Company (17) · Grupo Espanol de Investigacion en Sarcomas (1) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1) · Presage Biosciences (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · University of Miami (1)
United States (16) · Spain (8) · Germany (7) · Italy (6) · Belgium (4) · France (4) · Hungary (4) · Japan (4) · Poland (4) · United Kingdom (4) · Canada (3) · Australia (2) · Austria (2) · Brazil (2) · Denmark (2)
Gary Deutsch, MD (1) · Jaishri O. Blakeley, MD (1) · Kenneth Gundle, MD (1) · Marilyn Huang, MD, MS (1) · Salah-Eddin Al-Batran, Prof. Dr. (1) · Seth Pollack, MD (1)
PMID 27291997, PMID 28426120, PMID 28447475, PMID 30591028, PMID 32259228, PMID 32299817, PMID 33632930, PMID 37185961
2015 (3), 2016 (3), 2009 (2), 2017 (1), U01CA137443 (1)